secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001297184-25-000062
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96
----------------------------------------------------------------------------

- Net revenues of $191.8M, flat YoY vs $191.2M.
- GAAP net income of $17.4M ($0.37 diluted EPS) vs $40.4M ($0.78) in Q3 2024.
- Adjusted non-GAAP net income $44.7M ($0.93 diluted EPS) vs $49.6M ($0.96).
- BAQSIMI revenue grew 14% YoY; FDA approval and launch of iron sucrose injection noted.
- Nine-month 2025 GAAP net income $73.7M ($1.52 EPS) vs $121.6M ($2.32) prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000062/0001297184-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000062/amph-20251106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer